API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
DPI-386 (scopolamine hydrobromide) is a mAChRs inhibitor which is being evaluated in phase 3 clinical trials for the treatment of motion sickness in adults.
Lead Product(s): Scopolamine Hydrobromide
Therapeutic Area: Neurology Product Name: DPI-386
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.
Lead Product(s): Scopolamine Hydrobromide
Therapeutic Area: Neurology Product Name: DPI-386
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Aeronautics and Space Administration
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.
Lead Product(s): Scopolamine Hydrobromide
Therapeutic Area: Neurology Product Name: DPI-386
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.
Lead Product(s): Scopolamine Hydrobromide
Therapeutic Area: Neurology Product Name: DPI-386
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
DPI-386 (scopolamine hydrobromide) Intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.
Lead Product(s): Scopolamine Hydrobromide
Therapeutic Area: Neurology Product Name: DPI-386
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023